GlassScriptPhysician profile
Harper E Niver
NPI 1609336304
$1,220.50
in general payments reported to CMS, 2019-2025
11 companies · $749 in 2025
The $749 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.06 · 2023: $152 · 2024: $223 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $362.40 | 2024-2025 | Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $164.05 | 2024-2025 | Lynparza, Keytruda |
| Leica Microsystems INC. | $161.00 | 2025 | Mammotome Elite |
| Lilly USA, LLC | $119.44 | 2025 | Verzenio, Jaypirca |
| Boston Scientific Corporation | $97.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $81.98 | 2025 | |
| Medtronic, INC. | $77.42 | 2023 | Endoflip |
| Myriad Genetic Laboratories, INC. | $74.54 | 2023 | Myrisk |
| Eisai INC. | $44.70 | 2025 | |
| Incyte Corporation | $19.33 | 2025 | Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $18.58 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harper Niver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.